The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Https://twitter.com/Sareumplc/status/1722550740932014341?t=Y0dnBwGkdXcSqTsKLzCi8A&s=19
* HPRA approval to provide an Irish logistics hub for the distribution of allograft products in the EU
* New exclusive distribution agreement for Tissue Regenix's allograft products in Spain.
Double good news. Well done team TRX.
LH&K Mafuta
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase Patent Application No. 2020-555115 entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".
NXP002 is the Company's lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The granted patent describes a proprietary new form of the drug tranilast, uniquely enabling delivery via an inhaled nebulised formulation. Nuformix owns two patent applications relating to crystalline forms of tranilast, one of which had already been granted globally. This second patent application, which as has already been granted in the US, specifically addresses the novel tranilast forms being progressed by the Company as a potential novel IPF treatment.
Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we have received this Official Decision to Grant from the Japanese Patent Office. This provides confirmation that no prior art exists in relation to NXP002, which is very important given that this is the territory in which tranilast was first invented and where the vast majority of considerable subsequent development work has been conducted. The grant is therefore an important step forward for our lead asset NXP002. We expect the European grant to follow shortly, which will further support the Company's on-going partnering activities."
LH&K Mafuta
Https://www.edisongroup.com/research/sdc-1801-embarks-on-clinical-journey-in-fy23/32763/
It's because the trolls have closed their shorts and have gone to bother another board ... also "no news is good news" ... it's a waiting game asnd BOD only give out information when they really have to ... they are occupied with more important things methinks ... LH&K Mafuta
Great news ... onwards and upwards
Hot ... The problem with aging parents is that they need a lot of attention and that can be challenging ... but when they have gone you'll miss them ... well done for showing them you care ... an increasingly scarce trait in this hedonistic world ... LH&K Mafuta
Good progress and after tomorrow (possibly) looks like funding will be taken care of in the short term. LH&K Mafuta
Https://twitter.com/NuformixPlc/status/1701495004676469047?t=Q26_MJ5_W96-pQQ_uyAhHg&s=19
C79 ... good post ... I have taken a similar approach... although I don't block anyone ... perhaps it's my perverted sense of humour ... I get entertainment from the rantings of these idiots ... the science will prevail ... LH&K Mafuta